"Eli Lilly is betting big that generative AI can do more than just write code and create images. It can design cures for diseases."
"Insilico has developed 28 drugs using generative AI, with nearly half already in clinical trials. The company went public in Hong Kong in December and its shares are up more than 50% this year."
"CEO Alex Zhavoronkov said AI can synthesize molecules faster than traditional methods and cut years off research time."
"Eli Lilly called Insilico's AI-enabled discovery 'a powerful complement' to its own development work."
Eli Lilly has entered a $2.75 billion agreement with Insilico Medicine to utilize generative AI for drug discovery. Insilico will receive $115 million upfront, with additional payments based on regulatory milestones and sales. The company has developed 28 drugs using AI, with many in clinical trials. CEO Alex Zhavoronkov emphasized that AI can accelerate molecule synthesis and reduce research time. This partnership builds on a previous collaboration and coincides with Eli Lilly's $3 billion investment plan in China over the next decade.
Read at Entrepreneur
Unable to calculate read time
Collection
[
|
...
]